vs
Side-by-side financial comparison of Ouster, Inc. (OUST) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Ouster, Inc. is the larger business by last-quarter revenue ($48.6M vs $27.5M, roughly 1.8× Sanara MedTech Inc.). Ouster, Inc. runs the higher net margin — 8.2% vs -5.9%, a 14.1% gap on every dollar of revenue. On growth, Ouster, Inc. posted the faster year-over-year revenue change (48.9% vs 4.6%). Over the past eight quarters, Ouster, Inc.'s revenue compounded faster (34.2% CAGR vs 21.8%).
Ouster, Inc. is an American lidar technology company headquartered in San Francisco, California. It builds high-resolution, digital 3D lidar sensors for use in autonomous vehicles, industrial, robotics, drones, mapping, defense, and security systems.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
OUST vs SMTI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.6M | $27.5M |
| Net Profit | $4.0M | $-1.6M |
| Gross Margin | 42.9% | 93.2% |
| Operating Margin | 17.6% | 23.5% |
| Net Margin | 8.2% | -5.9% |
| Revenue YoY | 48.9% | 4.6% |
| Net Profit YoY | — | 5.3% |
| EPS (diluted) | $0.06 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $48.6M | — | ||
| Q4 25 | $62.2M | $27.5M | ||
| Q3 25 | $39.5M | $26.3M | ||
| Q2 25 | $35.0M | $25.8M | ||
| Q1 25 | $32.6M | $23.4M | ||
| Q4 24 | $30.1M | $26.3M | ||
| Q3 24 | $28.1M | $21.7M | ||
| Q2 24 | $27.0M | $20.2M |
| Q1 26 | $4.0M | — | ||
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $-21.7M | $-30.4M | ||
| Q2 25 | $-20.6M | $-2.0M | ||
| Q1 25 | $-22.0M | $-3.5M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $-25.6M | $-2.9M | ||
| Q2 24 | $-23.9M | $-3.5M |
| Q1 26 | 42.9% | — | ||
| Q4 25 | 60.2% | 93.2% | ||
| Q3 25 | 42.1% | 92.9% | ||
| Q2 25 | 45.2% | 92.5% | ||
| Q1 25 | 41.3% | 92.2% | ||
| Q4 24 | 43.8% | 91.4% | ||
| Q3 24 | 38.3% | 90.8% | ||
| Q2 24 | 33.7% | 90.0% |
| Q1 26 | 17.6% | — | ||
| Q4 25 | 1.5% | 23.5% | ||
| Q3 25 | -61.4% | 11.2% | ||
| Q2 25 | -76.5% | -0.1% | ||
| Q1 25 | -73.0% | -8.9% | ||
| Q4 24 | -85.1% | 18.6% | ||
| Q3 24 | -98.0% | 3.6% | ||
| Q2 24 | -93.6% | -14.3% |
| Q1 26 | 8.2% | — | ||
| Q4 25 | — | -5.9% | ||
| Q3 25 | -55.0% | -115.5% | ||
| Q2 25 | -58.8% | -7.8% | ||
| Q1 25 | -67.5% | -15.1% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | -91.1% | -13.2% | ||
| Q2 24 | -88.4% | -17.4% |
| Q1 26 | $0.06 | — | ||
| Q4 25 | $0.10 | $-0.32 | ||
| Q3 25 | $-0.37 | $-3.40 | ||
| Q2 25 | $-0.38 | $-0.23 | ||
| Q1 25 | $-0.42 | $-0.41 | ||
| Q4 24 | $-0.46 | $-0.18 | ||
| Q3 24 | $-0.54 | $-0.34 | ||
| Q2 24 | $-0.53 | $-0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $173.1M | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $275.6M | $5.9M |
| Total Assets | $381.5M | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $173.1M | — | ||
| Q4 25 | $208.6M | $16.6M | ||
| Q3 25 | $244.5M | $14.9M | ||
| Q2 25 | $226.5M | $17.0M | ||
| Q1 25 | $168.2M | $20.7M | ||
| Q4 24 | $172.0M | $15.9M | ||
| Q3 24 | $151.4M | $16.3M | ||
| Q2 24 | $184.2M | $6.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M |
| Q1 26 | $275.6M | — | ||
| Q4 25 | $261.7M | $5.9M | ||
| Q3 25 | $247.4M | $6.1M | ||
| Q2 25 | $221.0M | $35.4M | ||
| Q1 25 | $167.9M | $36.7M | ||
| Q4 24 | $180.9M | $39.4M | ||
| Q3 24 | $171.7M | $39.8M | ||
| Q2 24 | $170.6M | $41.7M |
| Q1 26 | $381.5M | — | ||
| Q4 25 | $349.5M | $72.9M | ||
| Q3 25 | $353.8M | $71.1M | ||
| Q2 25 | $321.8M | $98.8M | ||
| Q1 25 | $268.6M | $96.4M | ||
| Q4 24 | $276.1M | $88.1M | ||
| Q3 24 | $255.2M | $88.5M | ||
| Q2 24 | $309.9M | $73.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $3.9M |
| Free Cash FlowOCF − Capex | — | $3.9M |
| FCF MarginFCF / Revenue | — | 14.0% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-15.4M | $3.9M | ||
| Q3 25 | $-18.3M | $2.2M | ||
| Q2 25 | $-1.3M | $2.7M | ||
| Q1 25 | $-4.9M | $-2.0M | ||
| Q4 24 | $-2.6M | $932.0K | ||
| Q3 24 | $-3.8M | $2.1M | ||
| Q2 24 | $-21.6M | $-1.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-37.2M | $3.9M | ||
| Q3 25 | $-20.0M | $1.1M | ||
| Q2 25 | $-2.2M | $902.7K | ||
| Q1 25 | $-5.4M | $-3.7M | ||
| Q4 24 | $-4.0M | $859.9K | ||
| Q3 24 | $-4.3M | $2.0M | ||
| Q2 24 | $-22.0M | $-1.5M |
| Q1 26 | — | — | ||
| Q4 25 | -59.8% | 14.0% | ||
| Q3 25 | -50.7% | 4.2% | ||
| Q2 25 | -6.3% | 3.5% | ||
| Q1 25 | -16.6% | -15.9% | ||
| Q4 24 | -13.3% | 3.3% | ||
| Q3 24 | -15.4% | 9.4% | ||
| Q2 24 | -81.5% | -7.3% |
| Q1 26 | — | — | ||
| Q4 25 | 35.0% | 0.3% | ||
| Q3 25 | 4.3% | 4.0% | ||
| Q2 25 | 2.5% | 6.8% | ||
| Q1 25 | 1.7% | 7.4% | ||
| Q4 24 | 4.8% | 0.3% | ||
| Q3 24 | 2.0% | 0.0% | ||
| Q2 24 | 1.3% | 0.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OUST
| Product revenue | $48.2M | 99% |
| Royalties | $347.0K | 1% |
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
